Table 1 Baseline demographic and clinical characteristics of patients who completed baseline and follow-ups and of those who were not included in the study.
Included patients (n = 523) | Excluded patients (n = 577) | P value | |
|---|---|---|---|
Age in years, mean (SD) | 27.6 (7.4) | 26.6 (7.0) | 0.018 |
No. (%) male sex | 402 (76.9) | 426 (77.6) | 0.775 |
No. (%) white ethnicity | 449 (85.9) | 363 (72.6) | <0.001 |
WAIS IQ, mean (SD) | 97.4 (16.1) | 92.1 (15.6) | <0.001 |
Education patient, mean (SD) | 4.3 (2.0) | 3.8 (2.1) | <0.001 |
Education father; SES, mean (SD) | 5.1 (2.5) | 4.7 (2.6) | 0.014 |
Education mother; SES, mean (SD) | 4.4 (2.4) | 4.1 (2.5) | 0.054 |
No. (%) employed/student | 241 (46.1) | 184 (41.2) | 0.124 |
Illness duration in years, mean (SD) | 4.6 (4.2) | 3.9 (3.4) | 0.002 |
No. (%) recent onset of psychosis in the past year | 101 (19.3) | 168 (30.7) | <0.001 |
No. (%) DSM-IV schizophrenia diagnosis, 295.1,2,3 | 342 (65.4) | 341 (62.5) | 0.317 |
No. (%) antipsychotic drug use present state | 479 (91.6) | 434 (99.3) | <0.001 |
No. (%) clozapine use present state | 64 (12.2) | 81 (14.8) | 0.228 |
No. (%) cannabis abuse/dependency present state | 160 (30.6) | 179 (32.6) | 0.479 |
No. (%) other illicit drug use in the past | 324 (62.9) | 365 (69.5) | 0.024 |
PANSS positive symptoms, mean (SD) | 12.2 (5.1) | 13.3 (5.5) | 0.001 |
PANSS negative symptoms, mean (SD) | 13.3 (5.5) | 14.7 (6.3) | <0.001 |
PANSS general symptoms, mean (SD) | 27.0 (7.8) | 29.0 (8.8) | <0.001 |
PANSS total, mean (SD) | 52.4 (15.7) | 56.9 (17.5) | <0.001 |
Global assessment of functioning; symptoms, mean (SD) | 57.9 (16.0) | 53.5 (15.3) | <0.001 |
Global assessment of functioning; degree of disabilities, mean (SD) | 57.0 (15.6) | 51.3 (15.8) | <0.001 |
No. (%) GAF score ≥65 | 173 (33.1) | 94 (21.2) | <0.001 |
CAPE frequency symptoms, mean (SD) | 0.9 (0.5) | 0.9 (0.5) | 0.267 |
CANSAS number of needs, mean (SD) | 6.7 (3.8) | 7.8 (3.9) | <0.001 |
